Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 419,665 | 61,861 | 176,328 | 115,850 | 154,318 |
| Marketable Securities | 282,298 | 486,316 | 571,594 | 480,224 | 511,988 |
| Receivables | 346,035 | 316,339 | 304,621 | 308,455 | 285,743 |
| Inventories | 185,796 | 181,505 | 164,868 | 141,860 | 131,412 |
| TOTAL | $1,328,749 | $1,122,673 | $1,262,028 | $1,085,340 | $1,126,976 |
| Non-Current Assets | |||||
| PPE Net | 71,420 | 71,520 | 72,816 | 75,035 | 74,490 |
| Intangibles | 765,365 | 783,127 | 800,889 | 818,651 | 836,413 |
| Other Non-Current Assets | 55,698 | 76,579 | 60,799 | 84,451 | 80,151 |
| TOTAL | $892,483 | $931,226 | $934,504 | $978,137 | $991,054 |
| Total Assets | $2,221,232 | $2,053,899 | $2,196,532 | $2,063,477 | $2,118,030 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 710,685 | N/A | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 15,360 | 18,691 | 20,074 | 10,249 | 12,398 |
| Accrued Expenses | 111,183 | 115,591 | 130,305 | 128,851 | 96,417 |
| TOTAL | $837,228 | $134,282 | $150,379 | $139,100 | $108,815 |
| Non-Current Liabilities | |||||
| Long Term Debt | 800,072 | 1,509,100 | 1,507,447 | 1,505,798 | 1,504,154 |
| Other Non-Current Liabilities | 71,799 | 77,769 | 56,436 | 54,758 | 40,406 |
| TOTAL | $880,089 | $1,586,869 | $1,563,883 | $1,560,556 | $1,556,512 |
| Total Liabilities | $1,717,317 | $1,721,151 | $1,714,262 | $1,699,656 | $1,665,327 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 117,597 | 116,966 | 123,221 | 123,153 | 127,227 |
| Common Shares | 118 | 118 | 123 | 123 | 127 |
| Retained earnings | 502,146 | 361,033 | 477,964 | 359,869 | 397,629 |
| Other shareholders' equity | -22,258 | -28,403 | -3,413 | 3,829 | -6,939 |
| TOTAL | $503,915 | $332,748 | $482,270 | $363,821 | $452,703 |
| Total Liabilities And Equity | $2,221,232 | $2,053,899 | $2,196,532 | $2,063,477 | $2,118,030 |